SG Americas Securities LLC Sells 13,208 Shares of Certara, Inc. (NASDAQ:CERT)

SG Americas Securities LLC reduced its position in shares of Certara, Inc. (NASDAQ:CERT) by 65.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,839 shares of the company’s stock after selling 13,208 shares during the quarter. SG Americas Securities LLC’s holdings in Certara were worth $120,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CERT. BlackRock Inc. increased its position in Certara by 157.8% during the 1st quarter. BlackRock Inc. now owns 14,796,486 shares of the company’s stock valued at $356,743,000 after purchasing an additional 9,055,874 shares during the period. Vanguard Group Inc. increased its position in Certara by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 10,652,509 shares of the company’s stock valued at $141,466,000 after purchasing an additional 626,267 shares during the period. William Blair Investment Management LLC increased its position in Certara by 1.1% during the 3rd quarter. William Blair Investment Management LLC now owns 7,150,914 shares of the company’s stock valued at $103,974,000 after purchasing an additional 77,805 shares during the period. JPMorgan Chase & Co. increased its position in Certara by 2.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,900,626 shares of the company’s stock valued at $56,715,000 after purchasing an additional 102,591 shares during the period. Finally, State Street Corp increased its position in Certara by 0.7% during the 2nd quarter. State Street Corp now owns 3,245,871 shares of the company’s stock valued at $59,107,000 after purchasing an additional 21,619 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Insider Transactions at Certara

In other news, insider Patrick F. Smith sold 14,427 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now owns 50,091 shares in the company, valued at approximately $844,033.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Patrick F. Smith sold 14,427 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $844,033.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $18.00, for a total transaction of $54,000.00. Following the sale, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at $3,123,432. The disclosure for this sale can be found here. Insiders have sold 23,427 shares of company stock worth $405,095 in the last quarter. Company insiders own 2.60% of the company’s stock.

Certara Price Performance

CERT opened at $16.21 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.62 and a current ratio of 2.62. The stock has a market capitalization of $2.60 billion, a P/E ratio of -46.31, a P/E/G ratio of 1.76 and a beta of 1.63. The company’s 50-day simple moving average is $17.85 and its two-hundred day simple moving average is $16.15. Certara, Inc. has a 52-week low of $11.81 and a 52-week high of $24.96.

Certara (NASDAQ:CERT) last posted its earnings results on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.04). Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. The company had revenue of $88.01 million for the quarter, compared to the consensus estimate of $86.80 million. As a group, analysts predict that Certara, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CERT. JMP Securities began coverage on shares of Certara in a research report on Thursday, April 4th. They issued a “market perform” rating on the stock. SVB Leerink began coverage on shares of Certara in a research report on Monday, February 26th. They issued a “market perform” rating and a $19.00 target price on the stock. Barclays upped their target price on shares of Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Jefferies Financial Group upped their target price on shares of Certara from $14.00 to $15.50 and gave the stock a “hold” rating in a research report on Friday, March 1st. Finally, Leerink Partnrs reissued a “market perform” rating on shares of Certara in a research report on Monday, February 26th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Certara presently has a consensus rating of “Hold” and a consensus price target of $20.06.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.